 For those prescribers that go ahead and fill out that prior authorization, we're actually, we're rejecting about 84 percent, meaning that most of those patients are not actually diabetic and there's off-label use. Some doctors say that CVS Caremark's approach might cause more problems, however. Dr. Scott Isaacs is the president-elect of the American Association of Clinical Endocrinology. He says he might prescribe a diabetes drug to a weight loss patient and vice versa.